Skip to content

Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia

Impact of Intravenous Dexamethasone on the Duration of Sensory and Motor Block Following a Bupivacaine-based Spinal Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03078062
Enrollment
60
Registered
2017-03-13
Start date
2017-05-26
Completion date
2017-10-26
Last updated
2017-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Motor Block, Prolonged Sensory Block, Spinal Anesthesia

Keywords

Spinal anesthesia, Motor block, Sensory block, Dexamethasone

Brief summary

The purpose of this study is to assess the effect of a single-dose of intravenous dexamethasone 8 mg on the duration of sensory and motor blockade following spinal anesthesia with isobaric bupivacaine. The hypothesis of the study is that intravenous dexamethasone will significantly prolong (by more than 20 minutes) the duration of spinal anesthesia.

Detailed description

Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension. Using intravenous or intrathecal adjuvants to local anesthetics may prolong the duration of sensory and motor blockade following spinal anesthesia. Various intrathecal additives have been studied such as opioids, adrenalin, clonidine, dexmedetomidine, midazolam, ketamine, magnesium, ketorolac and neostigmine. Most of them failed to prolong the duration of spinal anesthesia and side-effects have restricted their use. Dexamethasone is a potent corticosteroid with a half-life of 36 to 72 hours and an onset of action of 1 to 2 hours. The safety of single doses of intravenous dexamethasone is well documented. Dexamethasone is widely used in anesthesia to prevent nausea and vomiting and treat post-extubation sore throat and postoperative shivering. It is also increasingly used in orthopaedic surgery to reduce opioid needs without increasing the risks of infection, wound dehiscence and osteonecrosis. The use of dexamethasone in the perioperative period reduces postoperative edema allowing early mobilization and improved functional recovery. Recent studies have demonstrated that both perineural and intrathecal administration of dexamethasone can prolong the duration of peripheral and spinal anesthesia. However, dexamethasone has not been approved by health authorities for these indications and thus, the safety of this practice remains controversial. A recent study has compared peripheral to intravenous administration of dexamethasone for interscalene blocks. This study demonstrated the equivalency of these regimens in increasing the analgesic duration of a single-shot interscalene block. The impact of intravenous dexamethasone on the duration of spinal anesthesia remains unknown. This study will investigate the effect of a single-dose of dexamethasone 8 mg on the duration of the sensory and motor block following spinal anesthesia. Sixty patients scheduled for lower body surgery under spinal anesthesia will be considered for this study. After placement of standard non-invasive monitoring, spinal anesthesia will be performed in the sitting position using a 25 gauge (GA) pencil point needle (Whitacre, Pencan). After aspiration of cerebrospinal fluid (CSF), a dose of isobaric 0.5% bupivacaine 12 mg will be injected. The aspiration of CSF will be repeated at the end of the injection. While performing spinal anesthesia, an intravenous infusion of dexamethasone 8 mg or placebo will be initiated according to randomization. Subsequently, the patient will be placed in supine position. Sensory block will be measured by loss of sensation to pinprick at 5, 10, 20 and 30 minutes following spinal anesthesia and then every 15 minutes until confirmation of regression by two dermatomes. Loss of sensation will be assessed every 30 minutes thereafter. Motor block will be assessed using the Bromage scale at the same frequency until full recovery. Sedation will be allowed during the performance of the spinal anesthesia technique and surgery. In case of unsatisfactory quality of spinal anesthesia, general anesthesia will be performed. At the end of surgery, patients will be transferred to the recovery room. Multimodal analgesia including celecoxib and acetaminophen will be administered. Pain will be assessed using a verbal numeric pain scale (VNPS) of 0 to 10, where 0 means No pain and 10 means Worst pain imaginable. Intravenous hydromorphone will be administered when VNPS is superior to 3. Postoperative nausea and vomiting will be managed with intravenous ondansetron, dimenhydrinate and haloperidol. Opioid intake, presence of side-effects and quality of sleep will be assessed during the first 24 hours following surgery.

Interventions

DRUGDexamethasone

Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia

DRUGNormal saline

Administration of a single-dose of Normal saline during spinal anesthesia

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Patients in both groups will receive the study drug (dexamethasone or placebo) in the same volume of normal saline. The study drug will be prepared by an independent assistant.

Intervention model description

Prospective, randomized, double-blind, placebo-controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing lower body surgery under spinal anesthesia * American Society of Anesthesiologists' physical status of 1 to 3

Exclusion criteria

* Contraindication to spinal anesthesia (coagulopathy, local infection at the site of injection) * Pre-existing neuropathy or nerve block that could compromise study assessments * Preoperative use of systemic corticosteroids * Allergy or hypersensitivity to local anesthetics, dexamethasone or other drugs used in this study * Patient refusal or inability to consent

Design outcomes

Primary

MeasureTime frameDescription
Regression of sensory block by 2 dermatomesAt regression of spinal anesthesia by 2 dermatomes, approximately 2 hours after surgeryLoss of pinprick sensation by Von Frey filaments from the injection of bupivacaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level

Secondary

MeasureTime frameDescription
Onset of sensory blockUp to 30 minutes following spinal anesthesiaTime from injection of bupivacaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation
Onset of motor blockUp to 30 minutes following spinal anesthesiaTime from injection of bupivacaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale
Quality of motor blockUp to 30 minutes following spinal anesthesiaMaximal Bromage score
Surgeon's satisfaction towards spinal anesthesiaAt the end of surgery, on the day of randomizationUnsatisfied or satisfied
Time to first analgesic requestFrom the end of surgery up to approximately six hours after surgery, on the day of randomizationFirst request by the patient for an analgesic or pain superior to 3 on a scale from 0 to 10; where 0 means no pain at all and 10 means worst pain imaginable
Opioid consumptionAt recovery room discharge, approximately one hour after the end of surgery on the day of randomization and 24 hours following surgeryTotal dose of opioids
Incidence of hypotensionFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgerySystolic blood pressure lower than 90 mm Hg
Duration of motor blockAt 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression of 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgeryUsing the Bromage scale from the time of injection of bupivacaine for spinal anesthesia until complete recovery of motor block
Incidence of nauseaFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryAny episode of nausea reported by the patient or nursing team
Incidence of vomitingFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryAny episode of retching or vomiting reported by the patient or nursing team
Incidence of urinary retentionFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryAny episode of urinary retention reported by the patient or nursing team
Incidence of shiveringFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryAny episode of shivering reported by the patient or nursing team
Incidence of headacheFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryAny episode of headache reported by the patient or nursing team
Quality of sleepAt 24 hours after surgeryDescribed by the patient as good or bad
Duration of sensory blockAt 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression by 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgeryLoss of pinprick sensation by Von Frey filaments from the injection of bupivacaine for spinal anesthesia until complete recovery
Incidence of bradycardiaFrom injection of bupivacaine for spinal anesthesia to 24 hours after surgeryHeart rate slower than 50 beats per minute

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026